ID
28392
Description
Phase II Study of AS1411 Combined With Cytarabine to Treat Acute Myeloid Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00512083
Link
https://clinicaltrials.gov/show/NCT00512083
Keywords
Versions (3)
- 6/29/17 6/29/17 -
- 1/10/18 1/10/18 - Julian Varghese
- 1/10/18 1/10/18 - Julian Varghese
Copyright Holder
Antisoma Research
Uploaded on
January 10, 2018
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Leukemia, Myeloid NCT00512083
Eligibility Leukemia, Myeloid NCT00512083
- StudyEvent: Eligibility
Description
Exclusion Criteria
Alias
- UMLS CUI
- C0680251
Description
Acute Promyelocytic Leukemia
Data type
boolean
Alias
- UMLS CUI [1]
- C0023487
Description
Blast crisis stage of chronic myeloid leukemia
Data type
boolean
Alias
- UMLS CUI [1]
- C0919644
Description
High-dose cytarabine
Data type
boolean
Alias
- UMLS CUI [1]
- C0010711
Description
Interval first onset of last complete remission and current relapse
Data type
boolean
Alias
- UMLS CUI [1,1]
- C0677874
- UMLS CUI [1,2]
- C0035020
Description
Primary refractory leukemia
Data type
boolean
Alias
- UMLS CUI [1,1]
- C0857127
- UMLS CUI [1,2]
- C0392920
Description
Relapsed patients, more than three previous treatment regimens
Data type
boolean
Alias
- UMLS CUI [1]
- C0392920
Similar models
Eligibility Leukemia, Myeloid NCT00512083
- StudyEvent: Eligibility
C0011900 (UMLS CUI [1,2])
C0035020 (UMLS CUI [1,2])
C0392920 (UMLS CUI [1,2])